290 related articles for article (PubMed ID: 30097824)
1. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
2. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
3. Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response.
Miller C; Guillaume D; Dusenbery K; Clark HB; Moertel C
J Neurosurg Pediatr; 2017 Mar; 19(3):319-324. PubMed ID: 28009226
[TBL] [Abstract][Full Text] [Related]
4. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
5. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
7. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
9. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
[TBL] [Abstract][Full Text] [Related]
10. Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma.
Knight T; Shatara M; Carvalho L; Altinok D; Poulik J; Wang ZJ
Pediatr Blood Cancer; 2019 Jan; 66(1):e27474. PubMed ID: 30251337
[No Abstract] [Full Text] [Related]
11. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
Boull C; Hook K; Moertel C; Maguiness S
Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
[TBL] [Abstract][Full Text] [Related]
14. Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
Paul MR; Pehlivan KC; Milburn M; Yeh-Nayre L; Elster J; Crawford JR
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e730-e737. PubMed ID: 32398601
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
18. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
Karajannis MA; Legault G; Fisher MJ; Milla SS; Cohen KJ; Wisoff JH; Harter DH; Goldberg JD; Hochman T; Merkelson A; Bloom MC; Sievert AJ; Resnick AC; Dhall G; Jones DT; Korshunov A; Pfister SM; Eberhart CG; Zagzag D; Allen JC
Neuro Oncol; 2014 Oct; 16(10):1408-16. PubMed ID: 24803676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
